Skip to content
Screener

AbbVie ABBV Q1 2025 earnings

Reported April 25, 2025 · Before market open

Revenue$13.3BBeat by $416.0M
EPS$2.46Beat by $0.08
Revenue estimate$12.9B
EPS estimate$2.38

Next report

Oct 30, 2026 (In 3 weeks)
Revenue estimate$17.3B
EPS estimate$3.86

Financials

Q1 2025

Income statement

See full
Revenue$13.3B+8.4%
Gross profit$9.3B+13.7%
Operating income$3.7B+33.4%
Net income$1.3B-6.1%
EPS (diluted)$0.72-6.5%

Balance sheet

See full
Cash & equivalents$5.2B-71.4%
Total debt$66.1B+3.6%
Total equity$1.4B-82.3%
Total assets$136.17B-8.5%

Cash flow

See full
Operating cash flow$1.6B-59.5%
CapEx$235.0M+21.8%
Free cash flow$1.4B-63.6%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$370.64B+14.9%
Enterprise value$431.58B+17.2%
P/E88.4×+34.5×
P/S6.5×+0.5×

Profitability

See full
Gross margin70.7%+8.4pp
Net margin7.3%-3.7pp
FCF margin26.8%-13.4pp

Returns & leverage

See full
Return on equity89%+32.7pp
Debt / equity46.6×+38.6×
Current ratio0.8×-0.2×

Segments

By product

See full
Skyrizi$3.4B+70.6%
Rinvoq$1.7B+57.2%
All other$1.3B+68.4%
Humira$1.1B-50.6%
Botox Therapeutic$866.0M+15.8%

FAQ

When did AbbVie report Q1 2025 earnings?
AbbVie (ABBV) reported Q1 2025 earnings on April 25, 2025 before market open.
What were AbbVie's Q1 2025 revenue and EPS?
AbbVie reported revenue of $13.3B and eps of $2.46 for Q1 2025.
Did AbbVie beat estimates in Q1 2025?
Revenue beat the consensus estimate of $12.9B by $416.0M. EPS beat the consensus estimate of $2.38 by $0.08.
How did AbbVie's Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 8.4% from $12.3B a year earlier and eps grew 6.5% from $2.31.
Where can I find AbbVie's Q1 2025 SEC filings?
You can read the 8-K earnings release (0001551152-25-000026) and the 10-Q periodic report (0001551152-25-000029) directly on SEC EDGAR. The filing index links above go to sec.gov.